These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 10192099)

  • 21. The effect of albumin conformation on the binding of warfarin to human serum albumin. The dependence of the binding of warfarin to human serum albumin on the hydrogen, calcium, and chloride ion concentrations as studied by circular dichroism, fluorescence, and equilibrium dialysis.
    Wilting J; van der Giesen WF; Janssen LH; Weideman MM; Otagiri M; Perrin JH
    J Biol Chem; 1980 Apr; 255(7):3032-7. PubMed ID: 7358725
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Binding of warfarin influences the acid-base equilibrium of H242 in sudlow site I of human serum albumin.
    Perry JL; Goldsmith MR; Williams TR; Radack KP; Christensen T; Gorham J; Pasquinelli MA; Toone EJ; Beratan DN; Simon JD
    Photochem Photobiol; 2006; 82(5):1365-9. PubMed ID: 16563025
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of alpha-1-acid glycoprotein, albumin and palmitic acid on the brain and salivary gland extraction of warfarin in rats.
    Urien S; Morin D; Tillement JP
    J Pharmacol Exp Ther; 1989 Feb; 248(2):781-5. PubMed ID: 2918479
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Blood distribution of levocetirizine, a new non-sedating histamine H1-receptor antagonist, in humans.
    Bree F; Thiault L; Gautiers G; Benedetti MS; Baltes E; Rihoux JP; Tillement JP
    Fundam Clin Pharmacol; 2002 Dec; 16(6):471-8. PubMed ID: 12685505
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Warfarin metabolites: stereochemical aspects of protein binding and displacement by phenylbutazone.
    Chan E; McLachlan AJ; Rowland M
    Chirality; 1993; 5(8):610-5. PubMed ID: 8305289
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exploring the interaction between Salvia miltiorrhiza and human serum albumin: Insights from herb-drug interaction reports, computational analysis and experimental studies.
    Shao X; Ai N; Xu D; Fan X
    Spectrochim Acta A Mol Biomol Spectrosc; 2016 May; 161():1-7. PubMed ID: 26926393
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influences of haemodialysis on the binding sites of human serum albumin: possibility of an efficacious administration plan using binding inhibition.
    Nishio T; Takamura N; Nishii R; Tokunaga J; Yoshimoto M; Kawai K
    Nephrol Dial Transplant; 2008 Jul; 23(7):2304-10. PubMed ID: 18390890
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detection of site-specific binding and co-binding of ligands to human serum albumin using 19F NMR.
    Jenkins BG; Lauffer RB
    Mol Pharmacol; 1990 Jan; 37(1):111-8. PubMed ID: 2300044
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evidence for a large and flexible region of human serum albumin possessing high affinity binding sites for salicylate, warfarin, and other ligands.
    Kragh-Hansen U
    Mol Pharmacol; 1988 Aug; 34(2):160-71. PubMed ID: 3412320
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ibuprofen and warfarin modulate allosterically ferrous human serum heme-albumin nitrosylation.
    Ascenzi P; Cao Y; Tundo GR; Coletta M; Fanali G; Fasano M
    Biochem Biophys Res Commun; 2011 Jul; 411(1):185-9. PubMed ID: 21726535
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Perfluorochemical emulsion effect on warfarin binding by fraction V human albumin.
    Parsons DL
    Arch Int Pharmacodyn Ther; 1987 Mar; 286(1):23-30. PubMed ID: 3592858
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The fluorescent probe prodan characterizes the warfarin binding site on human serum albumin.
    Moreno F; Cortijo M; González-Jiménez J
    Photochem Photobiol; 1999 Jan; 69(1):8-15. PubMed ID: 10063798
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Site I on human albumin: differences in the binding of (R)- and (S)-warfarin.
    Bertucci C; Canepa A; Ascoli GA; Guimaraes LF; Felix G
    Chirality; 1999; 11(9):675-9. PubMed ID: 10506426
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Binding of clometacin to human serum albumin. Interactions with clofibrate, indomethacin, salicylic acid and warfarin.
    Zini R; Barre J; D'Athis P; Tillement JP
    Biochem Pharmacol; 1983 Oct; 32(19):2909-14. PubMed ID: 6626262
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Study on the interaction of levocetirizine dihydrochloride with human serum albumin by molecular spectroscopy.
    Liu X; Du Y; Sun W; Kou J; Yu B
    Spectrochim Acta A Mol Biomol Spectrosc; 2009 Dec; 74(5):1189-96. PubMed ID: 19857990
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of fatty acids on the binding of warfarin and phenprocoumon to human serum albumin with relation to anticoagulant therapy.
    Vorum H; Honoré B
    J Pharm Pharmacol; 1996 Aug; 48(8):870-5. PubMed ID: 8887741
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stopped-flow studies on drug-protein binding. 1. Kinetics of warfarin binding to human serum albumin.
    Rietbrock N; Lassmann A
    Naunyn Schmiedebergs Arch Pharmacol; 1980 Sep; 313(3):269-74. PubMed ID: 7432558
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of binding sites, extent of binding, and drug interactions of oligonucleotides with albumin.
    Srinivasan SK; Tewary HK; Iversen PL
    Antisense Res Dev; 1995; 5(2):131-9. PubMed ID: 7580117
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cicletanine binding to human plasma proteins and erythrocytes, a particular HSA-drug interaction.
    Zini R; Morin D; Jouenne P; Tillement JP
    Life Sci; 1988; 43(25):2103-15. PubMed ID: 3210902
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of perfluorochemical emulsion components on human albumin binding of warfarin.
    Parsons DL; Nadkarni SR
    Arch Int Pharmacodyn Ther; 1987 Aug; 288(2):165-74. PubMed ID: 3675079
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.